Shire receives approval for VPRIV to treat type 1 Gaucher disease

Links shared publicly online about this topic.

918
total visits

Shire receives approval for VPRIV to treat type 1 Gaucher disease

Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.

View full resource at news-medical.net

Tags: Lipid Storage Disease, Gaucher Disease, Disease and Condition, Shire